Benzinga Pro
Marketfy
Financial Data & APIs
Events
Premarket Prep
Membership is Free
What are you waiting for? Sign up now!
Name:
Username available!
Username taken!
Email:
Email available!
Email taken!
Password:
Leave blank:
OR
Free Account Login
Click here to access your premium account
Username or email:
Password:
OR
Forgot password?
Contribute
Login
Join
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Retail Sales
Offerings
IPOs
Insider Trades
Biotech/FDA
Markets
Pre-Market
After Hours
Movers
Forex
Commodities
Options
Binary Options
Bonds
Futures
Global Economics
Previews
Reviews
Small-Cap
Cryptocurrency
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
ETFs
Tech
Start-Ups
Fintech
Investing
Best Online Brokers
Personal Finance
Compare Brokers
TD Ameritrade Review
Ally Invest Review
Etrade Review
Personal Capital Review
Tradestation Review
Market Overview
Tickers
Articles
Keywords
Search by keyword...
googlecse
More From PBYI
Summary
Ideas
Twitter ($PBYI)
All News
Analyst Coverage
Analyst Ratings
News Coverage
News
General
Contracts
Dividend Summaries
Dividend Calendar
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Press Releases
Earnings
Earning Summaries
Earnings Calendar
Guidance Summaries
Puma Biotechnology
PBYI
:NASDAQ
Add to Watchlist +
{{ portfolio.portfolio_name }}
You have no watchlists at this time, click "Manage watchlists" to create your first watchlist.
Manage watchlists
Sector:
Healthcare
Industry:
Biotechnology
63.25
1.35 (2.18%)
After Hours 63.3
(%)
Data as of Apr 25, 2018
Prev. Close
61.9
Price Open
61.9
Volume
330,246
Day's Range
60.8554 - 63.65
52 Wk Range
28.35 - 136.9
50 Day Moving Avg.
68.46
PE Ratio
0
Shares Outstanding
36.97M
Market Cap
2.34B
Trade PBYI stock with
recommended broker Ally Invest
. Commissions as low as $3.95.
1d
5d
1m
3m
1y
5y
YTD
Analyst Rating
View All Ratings
Date
Research Firm
Action
Current
Target
4/12/18
Barclays
Downgrades
Overweight
Equal-Weight
0.0
3/09/18
Stifel Nicolaus
Maintains
Buy
Buy
95.0
3/02/18
Barclays
Maintains
Overweight
Overweight
90.0
Headlines
Press Releases
Barclays Downgrades Puma Biotechnology to Equal-Weight
Eddie Staley
Thu, 12 Apr 2018 06:39:19 -0400
Puma Biotech, Pint Pharma Report Exclusive Licensing Deal To Commercialize Neratinib In Latin America
Paul Quintaro
Tue, 03 Apr 2018 08:45:39 -0400
Puma Biotechnology Announces that NERLYNX Has Been Included as a Treatment Option in the National Comprehensive Cancer Network
Paul Quintaro
Mon, 02 Apr 2018 08:49:16 -0400
Barclays Maintains Overweight on Puma Biotechnology, Lowers Price Target to $90.00
Vick Meyer
Fri, 02 Mar 2018 13:17:27 -0400
Puma Biotechnology Reports Q4 Adj. EPS $(1.03) vs $(1.98) Est., Sales $20.1M vs $20.0M Est.
Paul Quintaro
Thu, 01 Mar 2018 17:12:48 -0400
Puma Biotech Shares Quiet Premarket Following EMA Recommendation Against Approval Of Co.'s Neratin
Paul Quintaro
Fri, 23 Feb 2018 08:22:10 -0400
Leerink Partners Global Healthcare Conference Begins Today, Presenters Include: Dova Pharma, Heron Therapeutics, Sage Therapeutics, Enanta, The Medicines Company, Puma Biotech, Dicerna Pharma, Biogen, bluebird bio, and Alexion Pharma
Hal Lindon
Wed, 14 Feb 2018 08:06:46 -0400
Puma Biotechnology, CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize NERLYNX In China; Puma To Receive $30M Upfront And $40M In Potential Milestone Payments
Eddie Staley
Thu, 01 Feb 2018 17:22:29 -0400
Puma Biotech Reports Publication Of Results From Phase II SUMMIT Basket Trial On Neratinib In HER2, HER3 Mutant Cancers
Paul Quintaro
Wed, 31 Jan 2018 14:17:06 -0400
Puma Biotech Shares Ticking Modestly Lower As Traders Circulating FDA.gov Alert 'FDA limits packaging for anti-diarrhea medicine Loperamide (Imodium) to encourage safe use'
Paul Quintaro
Tue, 30 Jan 2018 11:58:22 -0400
{{ story.title }}
{{ story.author }}
{{ story.created }}
Show more
Loading articles...
Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Business Wire
2 hours ago
Free Research Reports on These Biotech Stocks -- Prothena, PTC Therapeutics, Pulmatrix, and Puma Biotech
PRNewswire
Apr 13, 2018
Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Business Wire
Apr 03, 2018
NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination With Capecitabine or Paclitaxel as Treatment Options for Patients With Breast Cancer Brain Metastases
Business Wire
Apr 02, 2018
Robbins Geller Rudman & Dowd LLP Announces Pending Class Action in the Puma Biotechnology, Inc. Litigation
Business Wire
Mar 28, 2018
Puma Biotechnology to Present at Cowen's Annual Healthcare Conference
Business Wire
Mar 06, 2018
Puma Biotechnology Reports Fourth Quarter and Full Year 2017 Financial Results
Business Wire
Mar 01, 2018
Puma Biotechnology, Inc. to Host Earnings Call
PRLive
Mar 01, 2018
Puma Biotechnology Receives Results of CHMP Formal Decision for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Business Wire
Feb 23, 2018
New Research Coverage Highlights SunCoke Energy Partners, Carrols Restaurant Group, First Financial, Emerson Electric, Puma Biotechnology, and Amgen — Consolidated Revenues, Company Growth, and Expectations for 2018
Globe Newswire
Feb 20, 2018
{{ story.title }}
{{ story.author }}
{{ story.created }}
Show more
Loading articles...
Partner Headlines
ASLAN Pharmaceuticals Updates U.S. IPO Plans
Seeking Alpha
Apr 18, 2018
ASLAN Pharmaceuticals Files For $86 Million U.S. IPO
Seeking Alpha
Apr 06, 2018
3 Things In Biotech, April 3: Alkermes Gets Into Trouble, Puma Gets Into Your Head, Myriad Gets Into Japan
Seeking Alpha
Apr 04, 2018
Your Daily Pharma Scoop: MediciNova Makes A Strong Comeback, Alkermes' Setback, BioLife Preliminary Q1 Results
Seeking Alpha
Apr 03, 2018
Puma Bio establishes Nerlynx commercialization in Latin America
Seeking Alpha
Apr 03, 2018
Puma Bio's Nerlynx in treatment guidelines for certain breast cancer patients
Seeking Alpha
Apr 02, 2018
Puma Biotechnology (PBYI) Up 10.2% Since Earnings Report: Can It Continue?
Zacks
Apr 02, 2018
3 Things In Biotech, March 26: A Focus On European Opinions
Seeking Alpha
Mar 27, 2018
Henderson Group Plc Buys Aptiv PLC, IQVIA Holdings Inc, The Home Depot Inc, Sells Delphi ...
GuruFocus
Mar 12, 2018
Puma Biotechnology Inc (PBYI) Files –…-K for the Fiscal Year Ended on December '–, ...
GuruFocus
Mar 09, 2018
{{ story.title }}
{{ story.author }}
{{ story.created }}
Show more
Loading articles...
Earnings
View Earnings
Q4 2017
EST
Actual
Surprise
EPS:
-1.98
-1.03
0.95
Rev:
20.01M
20.10M
90.00K
Q1 2018
EST
Actual
Surprise
EPS:
-1
Expected
2018-05-09
Rev:
58.50M
Brokerage Center
Compare All Online Brokerages